SCHEMBL1928208

SCHEMBL1928208

CC(=O)C1(C)CCc2c(C)c(O)c(C)c(C)c2O1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.78
PTGS2 P35354 1/20 0.78
CYP1A2 P05177 1/20 0.78
CYP3A4 P08684 1/20 0.78
TSHR P16473 1/20 0.78
ALOX5 P09917 4/20 0.48
NR1I2 O75469 2/20 0.46
ACHE P22303 2/20 0.45
MAOB P27338 1/20 0.45
CAPN1 P07384 1/20 0.45
MAPT P10636 2/20 0.45
LMNA P02545 2/20 0.45
TTPA P49638 2/20 0.45
MEN1 O00255 1/20 0.45
GSTP1 P09211 1/20 0.45
KMT2A Q03164 1/20 0.45
USP2 O75604 1/20 0.45
THRB P10828 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16247633 1.00 PTGS1 (0.78) PTGS1PTGS2CYP1A2CYP3A4TSHR
SCHEMBL8270579 1.00 PTGS1 (0.78) PTGS1PTGS2CYP1A2CYP3A4TSHR
SCHEMBL16369360 0.89 PTGS1 (0.60) PTGS1PTGS2CYP1A2CYP3A4TSHR
(R)-Trolox SCHEMBL615168 0.88 PTGS1 (1.00) PTGS1PTGS2CYP1A2CYP3A4TSHR
Trolox SCHEMBL4647438 0.88 PTGS1 (1.00) PTGS1PTGS2CYP1A2CYP3A4TSHR
Trolox SCHEMBL29375939 0.88 PTGS1 (1.00) PTGS1PTGS2CYP1A2CYP3A4TSHR
Trolox SCHEMBL3226 0.88 PTGS1 (1.00) PTGS1PTGS2CYP1A2CYP3A4TSHR
Trolox SCHEMBL1927837 0.88 PTGS1 (1.00) PTGS1PTGS2CYP1A2CYP3A4TSHR
Trolox SCHEMBL1651402 0.88 PTGS1 (1.00) PTGS1PTGS2CYP1A2CYP3A4TSHR
Trolox SCHEMBL29653919 0.88 PTGS1 (1.00) PTGS1PTGS2CYP1A2CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3713564-B1 COMPOUNDS AS MPGES-1 INHIBITORS KHONDRION IP B V (NL) 2023-11-15 EP disclosed
US-20230323250-A1 FABRIC TREATMENT COMPOSITIONS WITH ANTIOXIDANT MULTIMERS THE PROCTER & GAMBLE COMPANY 2023-10-12 US disclosed
WO-2023196452-A1 FABRIC TREATMENT COMPOSITIONS WITH ANTIOXIDANT MULTIMERS THE PROCTER & GAMBLE COMPANY (US) 2023-10-12 WO disclosed
US-11761953-B2 Mediation of in vivo analyte signal degradation SENSEONICS, INCORPORATED (US) 2023-09-19 US disclosed
EP-4241842-A2 NOVEL TREATMENT OF MITOCHONDRIAL DISEASES KHONDRION IP B.V. (NL) 2023-09-13 EP disclosed
EP-3606522-B1 NOVEL TREATMENT OF MITOCHONDRIAL DISEASES KHONDRION IP B V (NL) 2023-07-12 EP disclosed
US-20230160001-A1 NUCLEOTIDE CLEAVABLE LINKERS WITH RIGID SPACERS AND USES THEREOF FIRST-CITIZENS BANK & TRUST COMPANY 2023-05-25 US disclosed
WO-2022093189-A1 COMPOSITIONS COMPRISING LEUCO COMPOUNDS AND COLORANTS MILLIKEN & COMPANY (US) 2022-05-05 WO disclosed
US-11136535-B2 Leuco colorants as bluing agents in laundry care compositions THE PROCTER & GAMBLE COMPANY (US) 2021-10-05 US disclosed
US-20200308220-A1 AROMATIC-CATIONIC PEPTIDES CONJUGATED TO ANTIOXIDANTS AND THEIR USE IN TREATING COMPLEX REGIONAL PAIN SYNDROME CLINICAL RESEARCH INSTITUTE OF MONTREAL (CA) 2020-10-01 US disclosed
US-20070054900-A1 4-Phenlthiazole and 4-phenylimidizole derivatives and their use as medicaments for the treatment of neurodegenerative diseases, pain and epilepsy SOCIETE DE CONSEILS DE RECHERCHES ET (FR) 2007-03-08 US disclosed
US-20070021390-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments SCRAS 2007-01-25 US disclosed
EP-1675836-A1 DERIVATIVES OF 4-PHENYLTHIAZOLES AND 4-PHENYLIMIDAZOLES AND THE USE THEREOF AS MEDICAMENTS FOR TREATING NEURODEGENERATIVE DISEASES, PAIN AND EPILEPSY Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2006-07-05 EP disclosed
EP-1589007-A2 5-membered heterocycle derivatives, production thereof and their use as medicaments Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S) SAS (FR) 2005-10-26 EP disclosed
WO-2005035510-A1 DERIVATIVES OF 4-PHENYLTHIAZOLES AND 4-PHENYLIMIDAZOLES AND THE USE THEREOF AS MEDICAMENTS FOR TREATING NEURODEGENERATIVE DISEASES, PAIN AND EPILEPSY SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2005-04-21 WO disclosed
US-20050038087-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments IPSEN PHARMA S.A.S. (FR) 2005-02-17 US disclosed
US-20040132788-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-07-08 US disclosed
EP-1228760-A2 5-membered heterocycle derivatives, production thereof and use thereof as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2002-08-07 EP disclosed
EP-1223933-A2 5-MEMBERED HETEROCYCLE DERIVATIVES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2002-07-24 EP disclosed
WO-2001026656-A2 5-MEMBERED HETEROCYCLE DERIVATIVES AND USE THEREOF AS MONOAMINE OXIDASE INHIBITORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2001-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021390-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments PARK7, SNCA, COMT PTGS1 268/4885PTGS2 288/4885CYP1A2 298/4885
US-20050038087-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments OXER1, OPRL1, OPRK1 PTGS1 263/4885PTGS2 364/4885CYP1A2 173/4885
US-20040132788-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments OPRK1, HCN1, P2RX7 PTGS1 138/4885PTGS2 366/4885CYP1A2 143/4885
US-20200308220-A1 AROMATIC-CATIONIC PEPTIDES CONJUGATED TO ANTIOXIDANTS AND THEIR USE IN TREATING COMPLEX REGIONAL PAIN SYNDROME QDPR, TYR, MTPN PTGS1 2488/4885PTGS2 1677/4885CYP1A2 3422/4885
US-20070054900-A1 4-Phenlthiazole and 4-phenylimidizole derivatives and their use as medicaments for the treatment of neurodegenerative diseases, pain and epilepsy TPMT, P2RX4, CACNA1I PTGS1 159/4885PTGS2 191/4885CYP1A2 545/4885
US-11761953-B2 Mediation of in vivo analyte signal degradation SLC2A1, SLC2A8, SLC2A4 PTGS1 1005/4885PTGS2 1474/4885CYP1A2 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.